MiMedx Group, Inc. has agreed to acquire Sanara MedTech Inc. in a cash-and-stock transaction with an estimated enterprise value of approximately $350 million. The agreement was announced on July 29, 2026.
Under the proposed transaction, Sanara shareholders will receive $33 in cash plus 0.4735 shares of MiMedx common stock for each Sanara share. Based on MiMedx’s share price at the time of the announcement, the stock portion was worth approximately $2 per Sanara share, putting the implied consideration at around $35 per Sanara share.
The acquisition is designed to combine MiMedx’s regenerative medicine and surgical portfolio with Sanara’s surgical wound care, tissue repair, collagen, irrigation, and musculoskeletal products. The companies expect the combination to create a broader surgical and regenerative medicine platform.
Key Deal Details at a Glance
| Deal Detail | Information |
| Acquirer | MiMedx Group, Inc. |
| Target | Sanara MedTech Inc. |
| Announcement Date | July 29, 2026 |
| Deal Type | Merger / Acquisition |
| Approx. Enterprise Value | $350 million |
| Consideration | Cash + MiMedx Stock |
| Cash per Sanara Share | $33.00 |
| MiMedx Shares per Sanara Share | 0.4735 |
| Implied Stock Value at Announcement | Approximately $2 per share |
| Implied Total Consideration | Approximately $35 per Sanara share |
| Acquirer Ticker | Nasdaq: MDXG |
| Target Ticker | Nasdaq: SMTI |
| Expected Closing | Q4 2026, subject to conditions |
| Target After Closing | Wholly owned MiMedx subsidiary |
Company Introduction: MiMedx Group
MiMedx Group is a U.S.-based regenerative medicine company headquartered in Marietta, Georgia. The company is listed on Nasdaq under the ticker MDXG.
MiMedx develops and commercializes products used in wound care, burn care and surgical applications. Its business has historically focused on regenerative medicine technologies involving placental tissue.
The company has also been expanding its Surgical business, making Sanara’s surgical-focused portfolio strategically relevant to the acquisition.
In the second quarter of 2026, MiMedx reported approximately $64 million in net sales, while its Surgical product sales increased 15% year over year.
Company Introduction: Sanara MedTech
Sanara MedTech is a U.S.-based medical technology company focused primarily on the surgical market. It develops and commercializes products for surgical wound care, tissue repair, bone fusion and other surgical applications.
Its product portfolio includes:
- CellerateRX Surgical Powder
- BIASURGE Advanced Surgical Solution
- FORTIFY TRG Tissue Repair Graft
- FORTIFY FLOWABLE
- TEXAGEN
- ALLOCYTE Plus
- BiFORM
- ACTIGEN
Sanara is listed on Nasdaq under the ticker SMTI.
The company reported approximately $103.1 million in net revenue in 2025, compared with about $86.7 million in 2024.
Why Is MiMedx Acquiring Sanara?
The main objective is to expand MiMedx’s Surgical business.
MiMedx already has a strong presence in regenerative medicine and soft-tissue applications. Sanara adds products covering surgical wound management, collagen-based treatment, tissue repair, irrigation and musculoskeletal applications.
In simple terms:
MiMedx’s regenerative medicine and surgical products + Sanara’s surgical and tissue-repair products = a broader surgical platform.
The companies believe this combination can create opportunities to sell a wider range of products through their combined commercial networks.
Sanara’s Major Products
CellerateRX Surgical Powder
CellerateRX is one of Sanara’s important products.
It is made from Type I bovine hydrolyzed collagen and is used in surgical wound management. The product is designed to support the wound-healing process.
CellerateRX is one of the key revenue-generating products in Sanara’s portfolio.
BIASURGE
BIASURGE is an advanced no-rinse surgical irrigation solution.
It is designed to help clean wounds and remove debris and microorganisms during surgical procedures.
The product gives Sanara a presence in the surgical irrigation category, which complements MiMedx’s existing surgical portfolio.
Tissue Repair Products
Sanara also offers products such as FORTIFY TRG and FORTIFY FLOWABLE.
FORTIFY TRG is based on porcine small intestinal submucosa and is used for soft-tissue reinforcement and repair applications.
These products add another layer to Sanara’s tissue-repair portfolio.
Why Are Bone and Musculoskeletal Products Important?
One of the important aspects of the acquisition is Sanara’s exposure to bone and musculoskeletal applications.
Sanara’s portfolio includes products such as:
- ALLOCYTE Plus
- BiFORM
- ACTIGEN
These products are used in bone-related surgical procedures.
For MiMedx, this provides an opportunity to expand beyond its existing soft-tissue and regenerative medicine focus into additional surgical and musculoskeletal applications.
OsStic: A Potential Future Growth Product
Another important Sanara technology is OsStic BioAdhesive Advanced Bone Fixation.
OsStic is a synthetic injectable bio-adhesive technology being developed for bone-fixation applications.
Sanara has stated that OsStic received FDA Breakthrough Device designation and that the company was targeting a commercial introduction in 2027.
This means MiMedx is not only acquiring Sanara’s existing products and revenue. It is also acquiring access to Sanara’s development pipeline and potential future products.
However, future products should not be treated as guaranteed sources of revenue because commercialization, regulatory requirements and market adoption can affect their performance.
What Will Sanara Shareholders Receive?
The transaction uses a combination of cash and MiMedx stock.
For every Sanara share, shareholders will receive:
$33 in cash + 0.4735 MiMedx shares
At the time of the announcement, MiMedx’s relevant share price implied a value of approximately $2 for the stock component.
Therefore, the total implied consideration was approximately:
$33 + $2 = $35 per Sanara share
Because part of the consideration is paid in MiMedx shares, the value of the stock component can change as MiMedx’s share price changes.
How Will MiMedx Finance the Acquisition?
MiMedx plans to use a combination of existing cash and new debt financing.
The company received a commitment from Hayfin Capital Management for a $300 million, six-year senior secured term loan.
SEC filings also indicate that the transaction involves approximately $302 million in cash consideration and approximately 4.4 million MiMedx shares.
This means the acquisition will require substantial financing, making the company’s post-acquisition debt and interest costs important factors to monitor.
How Could MiMedx Benefit From the Acquisition?
1. Expansion of Surgical Revenue
Sanara gives MiMedx a larger surgical business.
MiMedx has said that the acquisition is expected to significantly expand its Surgical revenue base.
Management also expects the combined company to generate more than $400 million in revenue in 2027.
This is a forward-looking company estimate and actual results may differ.
2. A Larger Product Portfolio
The combined company would have products across several areas, including:
- Regenerative medicine
- Surgical wound care
- Collagen products
- Surgical irrigation
- Tissue repair
- Bone-related products
- Musculoskeletal applications
- Bone fixation technology
This broader portfolio could allow the combined company to serve more surgical procedures and customer needs.
Distribution and Cross-Selling Opportunities
Another important part of the deal is the companies’ existing commercial networks.
Sanara already has relationships with hospitals, surgeons, distributors and other healthcare customers.
After the acquisition, MiMedx could potentially introduce its products to Sanara’s existing customers, while Sanara’s products could be offered through MiMedx’s commercial network.
This is known as a cross-selling opportunity.
However, these opportunities depend on successful integration and actual customer adoption after the acquisition.
Expected Cost Synergies
MiMedx expects the transaction to generate more than $20 million in annual run-rate cost synergies.
Cost synergies can occur when two companies combine overlapping operations and reduce duplicate expenses.
Potential areas can include:
- Corporate expenses
- Administrative functions
- Public-company costs
- Sales infrastructure
- Other overlapping operating costs
The $20 million figure is management’s estimate and should therefore be viewed as a target rather than a guaranteed saving.
Sanara’s Recent Business Performance
Sanara was already generating revenue and growing before the acquisition.
In the second quarter of 2026, Sanara reported revenue of approximately $28.14 million, compared with about $25.80 million in the second quarter of 2025.
That represents year-over-year growth of approximately 9%.
For the first six months of 2026, Sanara generated approximately $55.94 million in revenue, compared with approximately $49.24 million during the same period of 2025.
This shows that MiMedx is acquiring an operating medical technology business rather than only an early-stage technology pipeline.
MiMedx’s Existing Business Position
MiMedx’s own financial performance is also important when analyzing this transaction.
The company reported approximately $64 million in net sales in Q2 2026.
Its Surgical product sales increased 15% year over year. At the same time, MiMedx’s overall business was affected by changes in Medicare reimbursement related to its Wound business.
MiMedx also announced a cost-reduction initiative in April 2026 targeting approximately $40 million in annualized savings.
Therefore, the Sanara transaction is part of a broader strategy to expand MiMedx’s Surgical business while it manages challenges in other parts of its portfolio.
Ownership After the Transaction
According to the SEC proxy materials, based on the September 1, 2026 share counts, existing MiMedx shareholders would own approximately 97.1% of the combined company, while former Sanara shareholders would own approximately 2.9%.
This means Sanara shareholders will receive MiMedx shares, but their overall ownership in the combined company will remain relatively small.
What Happens to Sanara’s Nasdaq Listing?
If the merger is completed, Sanara will no longer operate as a separately listed public company.
Its shares are expected to be delisted and deregistered, while Sanara will become a wholly owned subsidiary of MiMedx.
MiMedx will continue to trade on Nasdaq under the ticker MDXG.
What This Acquisition Means
The transaction can be understood through three major areas.
1. Product Expansion
MiMedx will gain access to Sanara’s established surgical products and development pipeline.
Products such as CellerateRX, BIASURGE and OsStic are particularly relevant to the transaction.
2. Surgical Market Expansion
MiMedx has been focusing on expanding its Surgical business, and Sanara’s surgical-focused portfolio fits directly into that strategy.
The acquisition could give MiMedx a broader presence across surgical wound care, tissue repair, bone and musculoskeletal applications.
3. Potential Financial Synergies
MiMedx expects more than $20 million in annual run-rate cost synergies and combined 2027 revenue of more than $400 million.
However, these are forward-looking estimates. The actual financial benefit will depend on integration, customer adoption, product performance and the cost of financing the transaction.
Key Risks and Challenges
1. Higher Debt
The acquisition requires substantial new financing, including a planned $300 million term loan.
This could increase the combined company’s debt obligations and interest expenses.
2. Integration Risk
MiMedx will need to integrate:
- Employees
- Sales teams
- Distribution networks
- Corporate systems
- Product portfolios
- Business operations
Successful integration will be important for achieving the expected synergies.
3. Product Development Risk
Products such as OsStic could provide future growth opportunities, but their future contribution is not guaranteed.
Regulatory requirements, launch timing, physician adoption and market demand can all affect future revenue.
4. Existing MiMedx Business Challenges
MiMedx’s Wound business has faced pressure from changes in Medicare reimbursement.
The Sanara acquisition may strengthen the Surgical business, but it does not automatically eliminate challenges affecting MiMedx’s existing Wound business.
Source: mimedx news
